About Respira Therapeutics
Respira Therapeutics is a company based in Albuquerque (United States) founded in 2010 was acquired by Gossamer Bio in September 2025. Respira Therapeutics has raised $9.11 million across 3 funding rounds from investors including Gossamer Bio, HHS and Sun Mountain Capital. The company has 6 employees as of December 31, 2021. Respira Therapeutics offers products and services including RT234-PAH. Respira Therapeutics operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Albuquerque, United States
- Employees 6 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Respira Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$9.11 M (USD)
in 3 rounds
-
Latest Funding Round
$224.94 K (USD), Grant
Aug 01, 2019
-
Investors
Gossamer Bio
& 3 more
-
Employee Count
6
as on Dec 31, 2021
-
Acquired by
Gossamer Bio
(Sep 25, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Respira Therapeutics
Respira Therapeutics offers a comprehensive portfolio of products and services, including RT234-PAH.
Inhaled treatment for pulmonary arterial hypertension to relieve breathlessness.
People of Respira Therapeutics
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Respira Therapeutics
Respira Therapeutics has successfully raised a total of $9.11M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $224.94 thousand completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Respira Therapeutics
Respira Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Gossamer Bio, HHS and Sun Mountain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Respira Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Respira Therapeutics
Investment portfolio details for Respira Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Respira Therapeutics
Detailed financials for Respira Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Respira Therapeutics Comparisons
Peer comparison for Respira Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Respira Therapeutics
Respira Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
Detailed competitors of Respira Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Respira Therapeutics
Complete news archive for Respira Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Respira Therapeutics
Respira Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Respira Therapeutics is headquartered in Albuquerque, United States. It is registered at Albuquerque, New Mexico, United States.
Respira Therapeutics is a funded company, having raised a total of $9.11M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Respira Therapeutics is 6.
Respira is a product development-stage company focused on pulmonary delivery of therapeutics for respiratory diseases. It is applying its patented, high-efficiency AOS Dry Powder Inhaler (DPI) technologies to uniquely enable the highly targeted lung delivery of drugs to treat pulmonary diseases. building an internal pipeline and also seeking partnerships for the use of our DPI products with proprietary drugs. Its lead product is RT234AOS-DPI, a combination of RT234 (a proprietary inhaled formulation of an off-patent drug) and its patented AOS-DPI to treat Pulmonary Arterial Hypertension.
Respira Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Respira Therapeutics offers RT234-PAH.
Respira Therapeutics has 4 investors. Key investors include Gossamer Bio, HHS, Sun Mountain Capital, and Cottonwood Technology Fund.